We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+0.03%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4B
AUM Growth
+$261M
Cap. Flow
+$281M
Cap. Flow %
7.02%
Top 10 Hldgs %
19.74%
Holding
679
New
127
Increased
246
Reduced
223
Closed
43

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$104M
2
AAPL icon
Apple
AAPL
+$60.7M
3
AMZN icon
Amazon
AMZN
+$47.5M
4
AXP icon
American Express
AXP
+$28.7M
5
TRV icon
Travelers Companies
TRV
+$27.2M

Top Sells

Rank Stock Value
1
FSLR icon
First Solar
FSLR
+$28.1M
2
JNJ icon
Johnson & Johnson
JNJ
+$28.1M
3
CLX icon
Clorox
CLX
+$26.2M
4
TJX icon
TJX Companies
TJX
+$24.8M
5
MCK icon
McKesson
MCK
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 24.39%
2 Financials 11.87%
3 Technology 10.68%
4 Communication Services 10.67%
5 Consumer Discretionary 9.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GOOGL icon
1
Alphabet (Google) Class A
GOOGL
$4.3T
$119M 2.97%
3,126,080
+82,800
+3% +$3.05M
GILD icon
2
Gilead Sciences
GILD
$165B
$108M 2.71%
1,186,785
+23,664
+2% +$2.13M
AMGN icon
3
Amgen
AMGN
$197B
$104M 2.61%
+700,333
New +$104M
PEP icon
4
PepsiCo
PEP
$185B
$79.6M 1.99%
781,090
+90,349
+13% +$8.93M
INTC icon
5
Intel
INTC
$488B
$71.9M 1.8%
2,235,943
-476,580
-18% -$14.6M
PG icon
6
Procter & Gamble
PG
$347B
$70M 1.75%
854,697
-34,685
-4% -$2.79M
AAPL icon
7
Apple
AAPL
$4.8T
$66M 1.65%
+2,436,472
New +$60.7M
JNJ icon
8
Johnson & Johnson
JNJ
$599B
$59.2M 1.48%
549,728
-271,111
-33% -$28.1M
CELG
9
DELISTED
Celgene Corp
CELG
$57.8M 1.45%
580,639
-78,061
-12% -$8.04M
MSFT icon
10
Microsoft
MSFT
$2.99T
$53.5M 1.34%
974,543
+92,691
+11% +$4.86M
AMZN icon
11
Amazon
AMZN
$2.69T
$49.4M 1.23%
+1,672,440
New +$47.5M
XOM icon
12
ExxonMobil
XOM
$615B
$48.2M 1.21%
579,847
-80,353
-12% -$6.44M
BIIB icon
13
Biogen
BIIB
$29.5B
$47M 1.17%
181,400
-61,619
-25% -$16.3M
META icon
14
Meta Platforms (Facebook)
META
$1.64T
$46M 1.15%
405,532
+55,434
+16% +$5.85M
T icon
15
AT&T
T
$153B
$41.6M 1.04%
1,414,882
-51,725
-4% -$1.43M
VZ icon
16
Verizon
VZ
$182B
$39.7M 0.99%
737,843
-21,702
-3% -$1.09M
ABBV icon
17
AbbVie
ABBV
$448B
$39.1M 0.98%
687,670
+129,988
+23% +$7.25M
YHOO
18
DELISTED
Yahoo Inc
YHOO
$38M 0.95%
1,037,624
+491,703
+90% +$15.4M
MMM icon
19
3M
MMM
$83B
$36.5M 0.91%
263,225
+106,970
+68% +$13.7M
PFE icon
20
Pfizer
PFE
$141B
$35.1M 0.88%
1,256,663
-184,726
-13% -$5.28M
CSCO icon
21
Cisco
CSCO
$436B
$32.5M 0.81%
1,146,615
+784,893
+217% +$20.2M
PH icon
22
Parker-Hannifin
PH
$120B
$31.7M 0.79%
286,861
+118,529
+70% +$11.9M
MRK icon
23
Merck
MRK
$307B
$31M 0.78%
618,284
+36,731
+6% +$1.8M
AXP icon
24
American Express
AXP
$240B
$30.1M 0.75%
+492,684
New +$28.7M
NKE icon
25
Nike
NKE
$64.5B
$29.6M 0.74%
483,526
-335,716
-41% -$20.3M

Similar funds

Candriam SCA's Q1 2016 Portfolio in Review

As of Q1 2016, Candriam SCA held 679 positions worth $4B, up 7% from $3.74B the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Candriam SCA deployed $281M of net new capital in Q1 2016, opening 127 new positions and adding to 246 existing holdings. Its largest new stake was Amgen: 700,333 shares worth $104M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 29% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was First Solar, an estimated $28.1M trimmed.

  • Candriam SCA's largest Q1 2016 buy was Amgen: 700,333 shares worth $104M.
  • Candriam SCA added most to Mead Johnson Nutrition Company in Q1 2016, an estimated $22.2M increase.
  • Candriam SCA's biggest Q1 2016 reduction was First Solar, cutting an estimated $28.1M.
  • Candriam SCA fully exited Avangrid, Inc. in Q1 2016, selling an estimated $9.6M.
  • Candriam SCA's ten largest holdings make up 20% of its $4B portfolio in Q1 2016.
  • Candriam SCA opened 127 new positions and closed 43 in Q1 2016.
  • Candriam SCA's portfolio value rose 7% quarter-over-quarter to $4B.

Based on Candriam SCA's 13F filing for Q1 2016, filed 27 Apr 2016.